First Results of the NeoALTTO Trial (BIG 01-06/EGF 106903): A Phase III, Randomized, Open Label, Neoadjuvant Study of Lapatinib, Trastuzumab, and Their Combination Plus Paclitaxel in Women with HER2-Positive Primary Breast Cancer

被引：23
|
作者：
Baselga, J.
Bradbury, I.
Eidtmann, H.
Di Cosimo, S.
Aura, C.
De Azambuja, E.
Gomez, H.
Dinh, P.
Fauria, K.
Van Dooren, V.
Paoletti, P.
Goldhirsch, A.
Chang, T-W
Lang, I.
Untch, M.
Gelber, R. D.
Piccart-Gebhart, M.
机构：
[1] Vall dHebron Univ Hosp, NeoALTTO Study Team, Barcelona, Spain
[2] FSS Ltd, Kincraig, Scotland
[3] Univ Hosp Kiel, Kiel, Germany
[4] Vall dHebron Univ Hosp, Breast Canc Ctr, Barcelona, Spain
[5] SOLTI Spanish Breast Canc Res Grp, Barcelona, Spain
[6] Inst Jules Bordet, B-1000 Brussels, Belgium
[7] Breast European Adjuvant Study Team, Brussels, Belgium
[8] Inst Nacl Enfermedades Neoplas, Lima, Peru
[9] Breast Int Grp, Brussels, Belgium
[10] GlaxoSmithKline, Collegeville, PA USA
[11] European Inst Oncol, Milan, Italy
[12] Natl Cheng Kung Univ Hosp, Tainan 70428, Taiwan
[13] Natl Inst Oncol, Budapest, Hungary
[14] Charite, Acad Hosp, D-13353 Berlin, Germany
[15] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/0008-5472.SABCS10-S3-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
S3-3
引用
收藏
页数：2
相关论文
共 50 条
  • [41] TEACH: Phase III study of lapatinib after completion of adjuvant chemotherapy in trastuzumab-naive women with HER2-positive breast cancer
    Moy, B.
    Maltzman, J. D.
    Rappold, E.
    Nicolodi, L.
    Williams, L. S.
    Goss, P. E.
    BREAST, 2009, 18 : S58 - S58
  • [42] Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
    Hurvitz, Sara A.
    Martin, Miguel
    Symmans, W. Fraser
    Jung, Kyung Hae
    Huang, Chiun-Sheng
    Thompson, Alastair M.
    Harbeck, Nadia
    Valero, Vicente
    Stroyakovskiy, Daniil
    Wildiers, Hans
    Campone, Mario
    Boileau, Jean-Francois
    Beckmann, Matthias W.
    Afenjar, Karen
    Fresco, Rodrigo
    Helms, Hans-Joachim
    Xu, Jin
    Lin, Yvonne G.
    Sparano, Joseph
    Slamon, Dennis
    LANCET ONCOLOGY, 2018, 19 (01): : 115 - 126
  • [43] Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in HER2-Positive Metastatic Breast Cancer
    Wardley, Andrew M.
    Pivot, Xavier
    Morales-Vasquez, Flavia
    Zetina, Luis M.
    Dias Gaui, Maria de Fatima
    Reyes, Douglas Otero
    Jassem, Jacek
    Barton, Claire
    Button, Peter
    Hersberger, Veronica
    Torres, Antonio Anton
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (06) : 976 - 983
  • [44] Predicting pathological complete response by the combination of microRNAs in patients with HER2-positive primary breast cancer who received neoadjuvant combination therapy of trastuzumab, lapatinib and paclitaxel: Results from JBCRG-16 (NeoLath) study
    Shimomura, A.
    Masuda, N.
    Kawauchi, J.
    Takizawa, S.
    Ichikawa, M.
    Matasuzaki, J.
    Kuroi, K.
    Hara, H.
    Yamamoto, N.
    Inoue, K.
    Suganuma, N.
    Aogi, K.
    Ohno, S.
    Tamura, K.
    Ochiya, T.
    Toi, M.
    CANCER RESEARCH, 2019, 79 (04)
  • [45] Results of Neoteam: A randomized multicenter phase II study of liposomal doxorubicin hydrochloride plus trastuzumab vs conventional doxorubicin both in combination with cyclophosphamide and followed by docetaxel plus trastuzumab as neoadjuvant treatment of HER2-positive primary breast cancer
    Pernas Simon, S.
    Rezai, M.
    Hauschild, M.
    Machiels, J. P.
    Paepke, S.
    Llombart Cussac, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [46] Neoadjuvant trial of bevacizumab (B) and trastuzumab (T) in combination with weekly paclitaxel (P) as neoadjuvant treatment in HER2-positive breast cancer: A phase II trial (AVANTHER). Analysis of biomarkers
    Fernandez, M.
    Martinez, N.
    Calvo, I.
    Garcia, E.
    Ugidos, L.
    Herrero, M.
    Quijano, Y.
    Duran, H.
    Garcia, M.
    Suarez, A.
    Lopez-Rios, F.
    Perez, D.
    Perea, S.
    Hidalgo, M.
    Garcia-Estevez, L.
    CANCER RESEARCH, 2013, 73
  • [47] Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS)
    Yamamoto, Yutaka
    Iwata, Hiroji
    Taira, Naruto
    Masuda, Norikazu
    Takahashi, Masato
    Yoshinami, Tetsuhiro
    Ueno, Takayuki
    Toyama, Tatsuya
    Yamanaka, Takashi
    Takano, Toshimi
    Kashiwaba, Masahiro
    Tsugawa, Koichiro
    Hasegawa, Yoshie
    Tamura, Kenji
    Tada, Hiroshi
    Hara, Fumikata
    Fujisawa, Tomomi
    Niikura, Naoki
    Saji, Shigehira
    Morita, Satoshi
    Toi, Masakazu
    Ohno, Shinji
    CANCER SCIENCE, 2022, 113 (09) : 3169 - 3179
  • [48] Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer
    Sara Tolaney
    Howard Burris
    Elaina Gartner
    Ingrid A. Mayer
    Cristina Saura
    Matthew Maurer
    Eva Ciruelos
    Agustin A. Garcia
    Frank Campana
    Bin Wu
    Yi Xu
    Jason Jiang
    Eric Winer
    Ian Krop
    Breast Cancer Research and Treatment, 2015, 149 : 151 - 161
  • [49] Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer
    Tolaney, Sara
    Burris, Howard
    Gartner, Elaina
    Mayer, Ingrid A.
    Saura, Cristina
    Maurer, Matthew
    Ciruelos, Eva
    Garcia, Agustin A.
    Campana, Frank
    Wu, Bin
    Xu, Yi
    Jiang, Jason
    Winer, Eric
    Krop, Ian
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 149 (01) : 151 - 161
  • [50] Lapatinib Plus Capecitabine in Women with HER-2-Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial
    Cameron, David
    Casey, Michelle
    Oliva, Cristina
    Newstat, Beth
    Imwalle, Bradley
    Geyer, Charles E.
    ONCOLOGIST, 2010, 15 (09): : 924 - 934
12345